SN
INKT icon

Sittner & Nelson’s MiNK Therapeutics INKT Stock Holding History

Sittner & Nelson’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$53 – 469
2024
Q1 		$53 Hold
6
– – ﹤0.01% 492
2023
Q4 		$62 Hold
6
– – ﹤0.01% 444
2023
Q3 		$64 Hold
6
– – ﹤0.01% 457
2023
Q2 		$122 Buy
+6
New +$120 ﹤0.01% 471

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sittner & Nelson's INKT Position: Q2 2024 in Review

Sittner & Nelson sold out of MiNK Therapeutics (INKT) in Q2 2024, closing a stake of 6 shares — an estimated $53 sold.

Sittner & Nelson first reported a position in INKT in Q2 2023 and held it in 4 quarters. The position peaked at $122 in Q2 2023. 29 funds tracked by Wall St. Rank hold INKT as of Q2 2024.

  • Sittner & Nelson reported no remaining MiNK Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Sittner & Nelson sold 6 MiNK Therapeutics shares in Q2 2024, an estimated $53.
  • Sittner & Nelson first reported a position in MiNK Therapeutics in Q2 2023 and held it in 4 quarters.
  • Sittner & Nelson's MiNK Therapeutics position peaked at $122 in Q2 2023.
  • 29 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2024.

Based on Sittner & Nelson's 13F filing for Q2 2024, filed 13 Aug 2024.